Background In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs)
affects immune response to antigens. Therefore, post-vaccination serological assessments …

Background In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection
in patients with MS (pwMS) under different DMTs and to identify correlates of reduced …

Background and Purpose: Stroke is reported as a consequence of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) infection in several reports. However, data are …

Introduction Since the onset of the novel coronavirus pandemic, several neurological
complications secondary to SARS‐CoV‐2 infection have been reported, affecting central nervous …

Extending the natalizumab interval after the 24th administration could reduce the risk of
progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the …

Guillain-Barré syndrome (GBS) is a peripheral nervous system disease caused by an
immune-mediated inflammatory mechanism, usually triggered by a previous infectious process or …

Background and purpose Although two doses of COVID‐19 vaccine elicited a protective
humoral response in most persons with multiple sclerosis (pwMS), a significant group of them …

Objective: To study the immunomodulatory effect of teriflunomide on innate and adaptive
immune cell populations through a pilot, open-label, observational study in a cohort of patients …

Background Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod
showed a reduced humoral response to mRNA-based SARS-CoV-2 vaccines, while the …

Background To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound
in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been …